Table 1.
Baseline demographics, clinical characteristics and adjuvant therapy regimens of resectable MM patients.
| Characteristic | No. % (n = 175) |
|---|---|
| Age | |
| Median | 60.0 |
| Range | 26.0-86.0 |
| Age category | |
| <65 | 116 (66.3) |
| >=65 | 59 (33.7) |
| Sex | |
| Female | 111 (63.4) |
| Male | 64 (36.6) |
| Primary Site* | |
| Nasal cavity and sinuses | 64 (36.6) |
| Oral cavity | 17 (9.7) |
| Anorectal | 29 (16.6) |
| Genital tract* | 47 (26.9) |
| Urinary tract | 6 (3.4) |
| Esophagus | 12 (6.8) |
| Lymphatic metastasis | |
| N | 144 (82.3) |
| Y | 31 (17.7) |
| Mutation status | |
| BRAF | 9 (5.1) |
| c-KIT | 8 (4.6) |
| NRAS | 16 (9.1) |
| Wild type | 116 (66.3) |
| Unknown | 26 (14.9) |
| LDH level | |
| ≤ULN | 158 (90.3) |
| >ULN | 11 (6.3) |
| Unknown | 6 (3.4) |
| Adjuvant therapy | |
| TMZ-based Chemotherapy | 100 (57.1) |
| High dose IFN-α2b | 75 (42.9) |
*Genital tract included the uterine cervix (6 cases)_and vulvovaginal primary lesions (41 cases).
LDH, lactate dehydrogenase; ULN, upper limit of normal; TMZ, temozolomide; IFN, interferon.